bluuebunny/crossref_metadata_2025_split huggingface dataset:
1323-P: Meta-analysis of Multiple Comorbidities Associated with Type 2 Diabetes
Authors: KHACHIKYAN LIANNA , WORKU HELINA , RAPISORA KRIZIA , PEREZ ELIZABETH , CHIU CHIA , KABO JOHN M. , HO NHUT 
Published: June 2023

Many meta-analyses focus on one comorbidity associated with Type 2 diabetes mellitus (T2DM). However, people living with T2DM experience more than one comorbidity. The primary objective of this study was to conduct a comprehensive systematic review and meta-analysis on recent published data, considering 43 individual comorbidities which we grouped into 11 disease categories to identify the most prevalent comorbidities occurring with people living with T2DM. PubMed database was searched for studies on T2DM and comorbidities prevalence in adults from 2015 - 2020. Meta-analysis estimates of comorbidities prevalence were generated using a random-effects model. ANOVA analysis, Bonferroni test, and chi-square analysis were conducted to examine the statistical significance of our results; see Figure 1. 22 studies with nearly 90 million patients were eligible and included. Hyperlipidemia/Obesity (33%) and acute circulatory diseases (28%) occur more frequently compared to other comorbidities in patients with T2DM. Our analysis shows acute circulatory diseases and hyperlipidemia/obesity are the most prevalent comorbidities for patients with T2DM.

Disclosure
L.Khachikyan: None. H.Worku: None. K.Rapisora: None. E.Perez: None. C.Chiu: Employee; Medtronic. J.M.Kabo: None. N.Ho: None.
1326-P: Diabetes Is Associated with a Higher Hearing Loss Risk in an Observational and Mendelian Randomization Study
Authors: LI TONGTONG , GAN WEI , FENG CHENGWU , LIU YUNAN , CAO YAYING , HAN HAN , FU DONGHENG , XING HUADONG , QIN HAIQIANG , SUN MENG , WANG MENG , ZONG GENG 
Published: June 2023

Observational studies on diabetes and hearing loss have been controversial, and their potential causal relationship has not been investigated. We conducted Mendelian randomization (MR) analyses to determine whether type 1 diabetes (T1D), type 2 diabetes (T2D), fasting insulin (FI), 2-h glucose (2hG), fasting glucose (FG), and glycated hemoglobin (HbA1c) were associated with hearing loss. Among 497,998 individuals in the UK biobank, T1D and T2D were identified by medical history in questionnaires and clinical records. Hearing loss was primarily defined by speech-in-noise tests in the better ear (SiN hearing loss, SiNHL) and secondarily identified by International Classification of Diseases code (ICD-defined hearing loss, ICDHL) and self-reported data (hearing difficulty, HDiff; hearing difficulty with noise, HDiffn; and hearing aid use, HAid). In observational analyses, odds ratios (ORs) in people with T1D than those without diabetes were 1.27 (95% CI 1.06-1.53) for SiNHL, 1.36 (1.14-1.62) for HAid, and 1.78 (1.49-2.12) for ICDHL. The corresponding ORs in people with T2D were 1.17 (1.09-1.24), 1.16 (1.08-1.23), and 1.25 (1.16-1.34), respectively. In MR analyses, genetically predicted T1D and T2D were associated with a higher risk of SiNHL (OR 1.02 per 1-unit higher log-odds of T1D 1.02 [1.00-1.03]; T2D 1.03 [0.99-1.06]). Further analysis of glycemic traits supported an inverse association of genetically elevated FI on SiNHL (per 1-log unit increase in pmol/L FI 0.71 [0.54-0.94]), and a positive association for genetically elevated 2hG (per 1-log unit increase in mmol/L 2hG 1.18 [1.06-1.31]). Results were largely robust to sensitivity analyses accounting for horizontal pleiotropy, sample overlap, and definitions of hearing loss. Our study suggested a potential causal relationship between diabetes and hearing loss risk. The finding warrants confirmation by larger population-based studies and experimental studies on potential biological pathways.

Disclosure
T.Li: None. M.Sun: None. M.Wang: None. G.Zong: None. W.Gan: Employee; Novo Nordisk A/S. C.Feng: None. Y.Liu: None. Y.Cao: None. H.Han: None. D.Fu: None. H.Xing: None. H.Qin: None.

Funding
National Science Fund for Excellent Young Scholars (81922060)
1328-P: Impact of Early Childhood-Onset Type 1 Diabetes on Brain Structural Trajectories (CLARiFY Study)
Authors: GBADEYAN OYETUNDE , MORAN CHRIS , BROWN AMY , SAKOWSKI STACEY A. , SRIKANTH VELANDAI , CAMERON FERGUS , NORTHAM ELISABETH A. , FELDMAN EVA L. , BEARE RICHARD 
Published: June 2023

Although childhood-onset of Type 1 diabetes (T1D) is associated with alterations in structural brain development, the influence of T1D over time remains poorly understood. We aimed to compare the trajectories of brain structure change in a sample of children with T1D to age-matched children without T1D. We recruited children presenting to a tertiary hospital in Australia between 1990 - 1992 into this prospective cohort study (Cognition and Longitudinal Assessment of Risk Factors over 30 Years (CLARiFY) Study). Brain magnetic resonance imaging (MRI) was performed at two time points, approximately 20 years apart. We examined for between-group differences in normalized brain volumes and cortical thickness (CT) across time using linear mixed models. A total of 127 images were available at timepoint 1 (77 with T1D, mean age=20 years, 43% female) and 68 at timepoint 2 (36 with T1D, mean age=37 years, 49% female). At timepoint 1, those with T1D had lower subcortical gray matter volume than those without T1D (p=0.01) but the remaining measures were similar. Across time, those with T1D had greater decline in cortical thickness (β=-2280, p=0.03) than those without T1D, with trajectories in other measures being similar (Table). In conclusion, these preliminary findings suggest that childhood-onset T1D is associated with lower subcortical gray matter and altered development of cortical gray matter over time.

Disclosure
O.Gbadeyan: None. C.Moran: None. A.Brown: None. S.A.Sakowski: None. V.Srikanth: None. F.Cameron: None. E.A.Northam: None. E.L.Feldman: None. R.Beare: None.

Funding
National Institutes of Health (R01DK129320)
133-LB: Proof-of-Concept Study Results with a New Osmotic-Pressure–Based Continuous Glucose Sensor
Authors: PFÜTZNER ANDREAS , HANNA MINA , THOMÉ NICOLE , JENSCH HENDRICK 
Published: June 2023

Background: The Sencell sensor (Lifecare AS, Bergen, Norway) uses glucose induced changes in an osmotic pressure chamber for continuous measurement of glucose concentrations in the subcutaneous tissue. A close to linear correlation between the raw sensor signal and the glucose concentration and a very long duration of use (of up to 6-12 months or longer) are theoretically to be expected. The final device is planned to have the size of a grain of rice and to be implanted employing wireless energy and data transfer.
Method: For a first clinical proof of concept study in humans, a wired version of the core sensing technology was embedded into a 4 mm needle and inserted into the abdominal subcutaneous tissue of healthy volunteers. The study was conducted to collect first human proof-of-concept performance data for algorithm development during meal experiments and for further device optimization. The raw data was analyzed after one-point calibration and minor trend correction in comparison to the Statstrip blood glucose meter and the Freestyle Libre 2 glucose sensor.
Results: Seven participants (5 female, 2 male, age: 49±11 years) delivered a total of 105 direct comparator data-points (vs. Statstrip blood glucose meter) during repeated meal experiments with observation periods between 2 h and up to 72 days. The osmotic-pressure sensor followed glucose changes similar to the FreeStyle Libre device and reached an MARD of 9.8% in comparison to StatStrip (87 % and 13 % of the datapoints were lying in zones A and B of the consensus error grid, respectively).
Conclusions: In this first human proof-of-concept study, the osmotic-pressure based continuous glucose sensor was shown to track s.c. glucose concentrations in a comparable manner as the Libre 2 needle sensor. The clinical performance characteristics of the first wired prototypes provide an encouraging perspective for the upcoming next development steps.

Disclosure
A. Pfützner: Consultant; Novo Nordisk A/S, Research Support; LifeScan Diabetes Institute, Speaker's Bureau; AstraZeneca, Stock/Shareholder; Lifecare A/S, Diakard. M. Hanna: None. N. Thomé: None. H. Jensch: None.

Funding
Lifecare AS (LIFC-SEN-001)
1336-P: Predicting the Progression of Stages of Neuropathy Using Routine Eye and Kidney Tests—An Application of Novel Statistical Methods in the Diabetes Control and Complications Trial (DCCT)
Authors: ERIK LOVBLOM LEIF , BRIOLLAIS LAURENT , TOMLINSON GEORGE , PERKINS BRUCE A. 
Published: June 2023

Despite recent advances, neuropathy screening is not consistently performed in clinical practice. We aimed to determine if neuropathy risk could be predicted using the trajectories of routinely-performed eye and kidney screening tests in T1D. We used 28-year data from the DCCT/EDIC study, available via the NIH public repository. We used the Early Treatment Diabetic Retinopathy Study Research (ETDRS) Group 23-point scale, albumin excretion rate (AER), and eGFR treated as longitudinal outcomes. Simultaneously, we represented neuropathy as a 3-state progressive multistate outcome using nerve conduction studies and the Michigan Neuropathy Screening Instrument (MNSI) for early-stage neuropathy and the occurrence of serious foot ulcer or amputation for late-stage neuropathy. To model these interrelated disease processes, we used and developed joint models with multistate submodels. Our “joint multistate model” accounted for interval censoring: due to the visit schedule, the exact time of transition to early-stage neuropathy was known only to occur in between consecutive visits. A Bayesian estimation procedure was used. We found that the risk of transition from no to early-stage neuropathy was affected by the current value of ETDRS, the current slope of ETDRS, and the current value of AER. For example, controlling for all covariates including eGFR, the there was a 23% higher rate of occurrence of this early-stage for a 3-step higher ETDRS scale. In the same model controlling for all covariates, progression from early-stage to late-stage neuropathy was affected mainly by AER (11% higher rate for a doubling of AER). Routinely-performed clinical eye and kidney test results can be leveraged to help identify the risk of neuropathy. Future work will develop dynamic predictions integrated into an electronic medical record.

Disclosure
L.Lovblom: None. L.Briollais: None. G.Tomlinson: None. B.A.Perkins: Advisory Panel; Dexcom, Inc., Insulet Corporation, Novo Nordisk, Sanofi, Vertex Pharmaceuticals Incorporated, Other Relationship; Abbott, Medtronic, Sanofi, Research Support; Novo Nordisk, Bank of Montreal (BMO).
1337-P: Association of Uncontrolled Diabetes with Periodontal Disease in U.S. Adults
Authors: VU GIANG , LITTLE BERT B. , KING CHRISTIAN , GURUPUR VARADRAJ P. , SHAKIB SHAMINUL 
Published: June 2023

Objectives: The purpose of this study was to analyze the relationship between uncontrolled diabetes with periodontal disease (PD) among adults in the US.
Methods: The study sample from the 2009-2014 National Health and Nutrition Examination Survey data included 10,071 US participants aged ≥ 30 years in a probability weighted sample. We used the Centers for Disease Control and Prevention/American Academy of Periodontology’s standard to measure PD status by using means of a full-month oral examination at 6 sites per tooth for periodontal probing depth and clinical attachment loss. We used self-reported response to the diabetes questionnaire and laboratory report of HbA1c to assess the participant’s diabetes status (no diabetes, diabetes with HbA1c &lt; 9%, diabetes with HbA1c ≥ 9%). Multiple logistic regression analysis was performed to examine the relationship between diabetes status with PD.
Results: Multiple logistic regression showed that PD was significantly associated with controlled diabetes (adjusted odds ratio (OR) = 1.32, 95% confidence interval (CI): 1.01 - 1.73, p &lt;0.05) and uncontrolled diabetes (OR = 2.48, 95% CI: 1.52 - 4.04, p &lt;0.001) after adjusting for covariates. PD’s protective factors of PD included annual dental visit, female gender, and college education. PD’s risk factors were smoking status, racial minorities, income &lt;200% Federal Poverty Guidelines, and older age.
Conclusions: Uncontrolled diabetes was significantly associated with a higher risk of periodontal disease among adults in the US. Physicians should work with dentists to strongly recommend patients with diabetes to check their glycemic level and have an annual dental visit.

Disclosure
G.Vu: None. B.B.Little: None. C.King: None. V.P.Gurupur: None. S.Shakib: None.
1338-P: Characteristics of Patients with Type 2 Diabetes without Nonalcoholic Fatty Liver Disease (NAFLD)
Authors: VALDEZ SAENZ ENRIQUE , GODINEZ LEIVA EDDISON , LOMONACO ROMINA , MARANGI STEPHEN A. , KALAVALAPALLI SRILAXMI , GONZALEZ MARIA A. , CHI XIAOFEI , ORTIZ ROCHA ANDREA , MOHSENI YASMINE , BARB DIANA , GURKA MATTHEW J. , SHARMA ANU , CUSI KENNETH 
Published: June 2023

About 70% of patients with type 2 diabetes mellitus (T2DM) have NAFLD which is a risk factor for cirrhosis and hepatocellular carcinoma. Many factors may be associated with more severe disease (i.e., insulin resistance, obesity). However, the metabolic profile of T2DM patients spared from having NAFLD and liver fibrosis is unclear. To this end, we recruited 266 patients with a history of T2DM without a known history of NAFLD (age: 59 ± 10 years; female 58.3 %; BMI: 33.0 ± 6.3 kg/m2, A1c: 7.0 ± 1.4 %) attending the outpatient university clinics. We performed a medical history, physical exam and measured routine/metabolic laboratories, liver fat (by CAP score ≥ 274 dB/m) and fibrosis (by liver stiffness measurement or LSM ≥7.0 kPa or F≥1) by elastography. A total of 32% patients did not have NAFLD, but when compared to NAFLD patients there were no differences in terms of age, gender, or race. Those without NAFLD had a lower mean BMI ± SD (29.6 ± 5.2 vs. 34.6 ± 6.2 kg/m2) and better glycemic control (mean A1c: 6.7 ± 1.3% vs. 7.2 ± 1.4%, both p&lt;0.05). Patients without NAFLD had lower plasma ALT levels (mean 21 ± 12 vs. 28 ± 19 U/L; p&lt;0.05). Patients with NAFLD had more severe (hepatic) insulin resistance (IR) (HOMA-IR: 3.0 ± 2.3 vs. 4.9 ± 3.2, p&lt;0.05), with more people having a HOMA-IR ≥3.0 (35% vs. 72%, p&lt;0.05). In multiple regression analysis, with a 95% CI, obesity (OR 4.0, 2.3-7.1), HOMA-IR (OR 3.1, 1.0-5.7), and worse glycemic control (A1c) (OR 1.7, 1.1-2.9) accounted for most of the difference between subjects with vs. without NAFLD. In NAFLD patients, comparing those with vs. without fibrosis, obesity (OR 2.8, 1.6-4.9) and elevated aminotransferases (OR 2.1, 1.3-3.2) accounted for most of the difference among patient. Conclusion: Patients with type 2 diabetes mellitus without NAFLD are usually more insulin sensitive and have a more favorable cardiometabolic profile than those with NAFLD. This highlights the role of insulin resistance and lipotoxicity in the development of NAFLD in this population.

Disclosure
E.Valdez saenz: None. D.Barb: None. M.J.Gurka: None. A.Sharma: None. K.Cusi: Consultant; Poxel SA, Altimmune, Arrowhead Pharmaceuticals, Inc., AstraZeneca, 89bio, Inc., Bristol-Myers Squibb Company, Lilly, Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Medscape, Myovant, Novo Nordisk, ProSciento, Quest Diagnostics, Sagimet, Sonic Incytes, Terns, Research Support; Echosens, Inventiva, LabCorp, Zydus. E.Godinez leiva: None. R.Lomonaco: None. S.A.Marangi: None. S.Kalavalapalli: None. M.A.Gonzalez: None. X.Chi: None. A.Ortiz rocha: None. Y.Mohseni: None.

Funding
National Institutes of Health (R01120331-01A1)
1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)
Authors: VALDEZ SAENZ ENRIQUE , GODINEZ LEIVA EDDISON , LOMONACO ROMINA , KALAVALAPALLI SRILAXMI , MARANGI STEPHEN A. , GONZALEZ MARIA A. , ORTIZ ROCHA ANDREA , CHI XIAOFEI , GURKA MATTHEW J. , BARB DIANA , SHARMA ANU , CUSI KENNETH 
Published: June 2023

Diabetes is a strong predictor of worse outcomes in nonalcoholic fatty liver disease (NAFLD), such as cirrhosis, CVD, and overall mortality. However, its true prevalence in clinical practice, and the role of obesity contributing to fibrosis, remain unclear. To this end, we recruited 759 patients without known NAFLD (35% with T2DM; age: 56 ± 11 years; BMI: 30.8 ± 6.5 kg/m2; female 59 %; ethnicity: Caucasian 75%, AA 14%, other 11%) attending outpatient endocrine/primary care clinics. We measured: 1) Routine laboratories; 2) Liver fat (CAP score ≥ 274 dB/m) and fibrosis (liver stiffness measurement or LSM) by elastography. The prevalence of NAFLD in T2DM was 68% vs. 44% in those without T2DM (p&lt;0.05). Comparing patients with vs. without T2DM, the presence of any liver fibrosis (LSM ≥7 kPa or F≥1) was 20% vs. 6%, of clinically significant fibrosis (LSM ≥8 kPa [moderate-to-severe] = F≥2) was 12% vs. 4%, and advanced fibrosis (LSM ≥ 9.7 kPa = F3/F4) was 7% vs. 1%, respectively (all p&lt;0.05). Obesity in T2DM promoted a much higher prevalence of steatosis (80% vs. 47% in T2DM without obesity) and of moderate-to-severe fibrosis (17% vs. 3%, respectively, both p&lt;0.05). In people without T2DM, obesity also played a major role regarding steatosis (obese: 66 % vs. non-obese: 28%) and moderate-to-severe fibrosis (F≥2: 8% vs. 1%, respectively; both p&lt;0.05). Worse glycemic control in people with T2DM (A1c ≥7.0% vs. &lt;7.0%) led to a higher prevalence of steatosis (75% vs. 62%) and of fibrosis (24% vs 18%; both p&lt;0.05). In multiple regression analysis, with a 95% CI, obesity in T2DM was the most significant risk factor for steatosis (OR 2.8, 1.9-4.2) and fibrosis (OR 3.4, 2.1-5.3). Conclusion: People with T2DM are at a very high risk of hepatic steatosis and severe fibrosis. Obesity is a major risk factor for worse disease, even in the absence of diabetes. These findings strongly support recent ADA recommendations to screen people with T2DM and obesity and cardiometabolic risk factors for moderate-to-severe fibrosis.

Disclosure
E.Valdez saenz: None. D.Barb: None. A.Sharma: None. K.Cusi: Consultant; Poxel SA, Altimmune, Arrowhead Pharmaceuticals, Inc., AstraZeneca, 89bio, Inc., Bristol-Myers Squibb Company, Lilly, Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Medscape, Myovant, Novo Nordisk, ProSciento, Quest Diagnostics, Sagimet, Sonic Incytes, Terns, Research Support; Echosens, Inventiva, LabCorp, Zydus. E.Godinez leiva: None. R.Lomonaco: None. S.Kalavalapalli: None. S.A.Marangi: None. M.A.Gonzalez: None. A.Ortiz rocha: None. X.Chi: None. M.J.Gurka: None.

Funding
National Institutes of Health (R01120331-01A1)
1347-P: Utility of Fibrosis-4 (FIB-4) and Nonalcoholic Fatty Liver Disease Fibrosis Scores (NFS) for Liver Fibrosis Screening in Asian-Indians with Type 2 Diabetes—A Cross-Sectional Observational Study
Authors: V RAVI TEJA K. , CHANDEL SHIVANI 
Published: June 2023

Background: Fibrosis-4 (FIB-4) and the Nonalcoholic fatty liver disease fibrosis score (NFS) are suggested by American Diabetes Association Standard of Care 2023 for Liver fibrosis screening in type 2 diabetes (T2D).
Aim: Utility of FIB-4 and NFS to detect liver fibrosis in Asian-Indians with T2D.
Methods: This study included a total of 120 patients who underwent NAFLD screening from July 2022 to December 2022, recruited from Liver Clinic of an Endocrine speciality centre. Vibration Controlled Transient Elastography [VCTE (Fibroscan 430 Mini Plus, Echosens, France)] was used. After excluding alcoholics and nondiabetes patients we had total 73 people with T2D and we calculated FIB-4 and NFS for 46 patients. Liver Stiffness measurement (LSM) in KiloPascals (KPa) cut-off values used are - F0 till 7 kPa, F1 is 7 - 10 kPa, F2 is 10 - 13 kPa, F3 is 13 - 16 kPa and F4 is &gt; 16 kPa. FIB-4 and NFS were calculated using https://www.mdcalc.com.
Results: The mean age was 54.6 ± 12.4 years, mean body mass index (BMI) was 27.3 ± 3.7 kg/m2 and 14 (30.4%) were women. Overweight seen in 15.2 % (n=7) and obesity in 69.6 % (n=32). The mean values, Serum Albumin (5.1±2.4 g/dl), SGOT (20.7±8.9 U/L), SGPT (24.0 ±15.1 U/L), Platelet Count (2.7±0.8 x 105) Hba1c % (8.8±2.4) and LSM (6.4 ± 2.6 KPa). NFS grades: F0-F2 in 24 (52.2%), indeterminate in 18 (39%) and F3-F4 in 4 (8.7%). FIB-4 grades: F0-F1 in 40 (86.9%) and F2-F3 in 6 (13.1%). But on VCTE as per LSM it was found F0 in 32 (70%), F1 in 9 (19.6%), F2 in 4 (8.7%) and F4 in 1 (2.2%). We noticed that LSM had significant positive correlation with BMI (p=0.001), SGOT (p=0.04) and SGPT (p=0.011) which are components of FIB-4 and NFS but LSM did not significantly correlate with NFS (p=0.96) and FIB-4 score (p=0.79).
Conclusions: FIB-4 and NFS may be sub-optimal for screening Fibrosis in Asian-Indians with T2D. BMI can be considered as potential first step to identify at risk for liver fibrosis in T2D.

Disclosure
K. Ravi Teja: None. S. Chandel: None.
1348-P: Glycemic Control Is Associated with the Histological Severity of Nonalcoholic Fatty Liver Disease
Authors: MIYAKE TERUKI , FURUKAWA SHINYA , MATSUURA BUNZO , YOSHIDA OSAMU , MIYAZAKI MASUMI , SHIOMI AKIHITO , KANZAKI SAYAKA , NAKAGUCHI HIRONOBU , ABE MASANORI , HIASA YOICHI 
Published: June 2023

Background: Diabetes mellitus (DM) is a major risk for progression of nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL). Although DM influences on the pathophysiology of NASH, the impact of glycemic control status on the histological severity of NASH is unclear.
Methods: We conducted an observational study of 331 patients (140 men and 191 women) diagnosed with nonalcoholic fatty liver disease (NAFLD) by liver biopsy. Impact of glycemic control status on histological severity of NAFLD was evaluated by comparison of the four divided groups, based on the hemoglobin A1c (HbA1c) levels: HbA1c ≤5.4%; 5.5-6.4%; 6.5-7.4%; and ≥7.5%, at the time of liver biopsy. The histological severity of NAFLD was determined by fibrosis staging; stage 0-4, and NAS score; 0-8 points. The advanced liver fibrosis and the high NAS score were defined as stage 3-4 and 5-8 points, respectively.
Results: Higher HbA1c groups (5.5-6.4%; 6.5-7.4%; and ≥7.5%) were associated with advanced fibrosis compared to the lowest HbA1c group. In the multivariate analysis, the HbA1c 6.5-7.4% group was significantly associated with advanced fibrosis compared to the lowest HbA1c group after adjusting for age, sex, hemoglobin, alanine aminotransferase, and creatinine levels. When further controlling for body mass index, as well as uric acid, total cholesterol, and triglyceride levels, HbA1c 5.5-6.4%, 6.5-7.4%, ≥7.5% groups were significantly associated with advanced fibrosis compared to the lowest HbA1c group. These HbA1c groups (5.5-6.4%; 6.5-7.4%; and ≥7.5%) were also associated with higher NAFLD activity scores, these associations remained significant in the multivariate analysis.
Conclusions: The glycemic control status is strongly associated with the histological severity of NAFLD, even with mild deterioration in glycemic control. Therefore, adequate glycemic control in NAFLD patients might be important in improving NAFLD activity and preventing progression to NASH.

Disclosure
T.Miyake: None. Y.Hiasa: None. S.Furukawa: Speaker's Bureau; Kowa Company, Ltd., Ono Pharmaceutical Co., Ltd., Sanofi, Novo Nordisk, Eli Lilly Japan K.K. B.Matsuura: None. O.Yoshida: None. M.Miyazaki: None. A.Shiomi: None. S.Kanzaki: None. H.Nakaguchi: None. M.Abe: None.